Canine Pancreatitis: NAVLE Study Guide

Canine pancreatitis shows up on the NAVLE reliably, and the exam tests it in a specific way: they give you a signalment, a dietary history, and a set of clinical signs, then ask you to pick the right diagnostic test or treatment decision. Know the breeds, know cPLI interpretation, and know why the old NPO rule got thrown out.

Pathophysiology

The pancreas secretes digestive enzymes as inactive precursors — trypsinogen, chymotrypsinogen, proelastase. Normally, activation happens in the small intestine via enteropeptidase. Pancreatitis begins when trypsinogen activates prematurely inside the pancreatic acinar cells. Once trypsin is active in the wrong place, it sets off a cascade: autodigestion of pancreatic tissue, release of inflammatory mediators, local edema and necrosis, and — in severe cases — systemic spillover causing SIRS, DIC, and ARDS.

Dietary fat is the key trigger. High-fat meals cause a surge in pancreatic secretion. In dogs with impaired lipid clearance (hypertriglyceridemia), the pancreatic environment is already primed for this kind of insult.

Who Gets It: Breed Risk and Predispositions

The NAVLE will hand you a signalment. These are the breeds that should immediately put pancreatitis on your differential:

Clinical Signs

The classic presentation is acute vomiting, anorexia, and cranial abdominal pain. Dogs adopt the “prayer position” (front end down, hindquarters elevated) to relieve visceral pain. Severe cases add fever, marked dehydration, and signs of shock. Diarrhea may be present but is less prominent than vomiting.

Physical exam findings to flag: cranial abdominal tenderness on palpation, tachycardia, weak pulses in severe cases, and occasionally icterus from concurrent biliary obstruction.

Diagnosis

No single test is gold standard. The diagnosis is clinical — meaning you integrate signalment, history, signs, imaging, and serology.

Spec cPL (Canine Pancreatic Lipase)

This is the most specific serum biomarker for pancreatic inflammation in dogs. It uses monoclonal antibodies directed against pancreatic lipase specifically — no cross-reactivity with lipases from other tissues. It is unaffected by hemolysis, lipemia, or icterus.

Serum lipase using DGGR substrate assays is available on standard chemistry panels but is not specific for pancreatic lipase — it detects lipases from multiple tissues and is significantly affected by lipemia, which is a problem in the exact breeds predisposed to pancreatitis. Serum amylase is even less reliable and should not drive your diagnosis.

Abdominal Ultrasound

Sensitivity is roughly 42–68%, so a normal-appearing pancreas does not rule out pancreatitis. When findings are present, the combination of pancreatic enlargement, hypoechoic pancreatic parenchyma, and hyperechoic peripancreatic mesentery achieves specificity around 92%. The hyperechoic mesentery reflects fat saponification from leaked pancreatic enzymes — this is the most specific individual finding.

Radiographs

Abdominal radiographs are insensitive but supportive. Look for a “sentinel loop” (focal gas-filled duodenum) or generalized loss of detail in the cranial abdomen — the so-called “ground-glass” appearance from peritoneal effusion. These findings put pancreatitis on the list; they do not confirm it.

Acute vs. Chronic Pancreatitis

Treatment

IV Fluid Therapy

Fluids are the cornerstone of management. Pancreatitis causes third-spacing, vomiting-related fluid losses, and reduced intake. Isotonic crystalloids (LRS, Plasmalyte) are first-line. Correct dehydration, then maintain. Watch for electrolyte derangements — hypokalemia is common from vomiting and anorexia.

Pain Management

Pancreatitis hurts. Inadequately treated pain slows recovery and worsens anorexia. Opioids are the mainstay: buprenorphine for mild-to-moderate cases, methadone or fentanyl CRI for severe cases. Do not skip analgesia because the dog “isn’t crying.”

Anti-emetics

Maropitant (Cerenia) is the standard — it works centrally (NK1 receptor) and has some visceral analgesic effect. Ondansetron can be added for refractory vomiting. Metoclopramide is a second-line option.

Early Enteral Nutrition

Parenteral nutrition (PN) is reserved for patients who cannot tolerate any enteral route despite adequate antiemetic therapy. PN is not first-line and carries its own complication risks.

Long-Term Dietary Management

Lifelong low-fat, highly digestible diet fed in small frequent meals. No table scraps. No high-fat treats. For Miniature Schnauzers with concurrent hypertriglyceridemia, fat restriction is especially critical. Omega-3 supplementation may help reduce triglyceride levels in some dogs.

Complications

Diabetes mellitus: Chronic pancreatitis destroys beta cells through progressive fibrosis. The result is pancreatogenic (Type 3c) DM — often brittle and harder to regulate than typical canine DM because alpha cells that produce glucagon are damaged too.

Exocrine pancreatic insufficiency (EPI): Acinar cell destruction from recurrent inflammation eventually exceeds the pancreatic reserve (>90% of functional mass must be lost before clinical EPI develops). Signs are classic: weight loss despite polyphagia, voluminous pale fatty stool, and poor body condition. Treat with pancreatic enzyme supplementation (pancrelipase) and a low-fat diet.

SIRS and DIC: Systemic spillover of activated enzymes and inflammatory cytokines. Watch for tachycardia, fever, abnormal WBC, and coagulation changes. ARDS is a recognized pulmonary complication in severe cases — acute tachypnea and hypoxemia in a pancreatitis patient should prompt thoracic radiographs.

Fuzapladib (Panoquell-CA1)

A newer adjunctive option worth knowing for the boards. Fuzapladib sodium is an LFA-1 activation inhibitor that blocks neutrophil extravasation into pancreatic tissue. It received conditional FDA approval for managing clinical signs of acute-onset canine pancreatitis. Administered at 0.4 mg/kg IV once daily for 3 consecutive days alongside standard supportive care. Not a replacement for fluids and analgesia — adjunctive.